Denali Therapeutics Inc
DNLI12.750USD
-0.430-3.26%
收盘 09/19, 16:00（美东）报价延迟15分钟
1.86B总市值
亏损市盈率 TTM
关于 Denali Therapeutics Inc 公司
Denali Therapeutics Inc. 是一家生物制药公司。该公司专注于开发一系列候选产品，这些产品经过设计可穿过血脑屏障 (BBB)，用于治疗神经退行性疾病和溶酶体贮积症。该公司拥有小分子和生物治疗药物组合，包括七种适应症的七种临床开发候选产品以及临床前治疗候选产品。其三个后期开发项目包括用于治疗粘多糖贮积症 II (MPS II) 的 tividenofusp alfa (DNL310)；用于治疗帕金森病的 BIIB122/DNL151 (LRRK2 抑制剂)；以及用于治疗肌萎缩侧索硬化症 (ALS) 的 DNL343 (eIF2B 激活剂)。SAR443820/DNL788 (RIPK1 抑制剂) 正在针对多发性硬化症 (MS) 的 II 期研究中进行评估。此外，该公司还开展了 TAK-594/DNL593 治疗额颞叶痴呆-颗粒蛋白 (FTD-GRN) 的 I/II 期研究，以及 DNL126 治疗 MPS IIIA (Sanfilippo 综合征) 的 I/II 期研究。
公司简介
公司代码DNLI
公司名称Denali Therapeutics Inc
上市日期Dec 08, 2017
CEODr. Ryan J. Watts, Ph.D.
员工数量422
证券类型Ordinary Share
年结日Dec 08
公司地址161 Oyster Point Blvd.
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94080
电话16508668547
网址https://www.denalitherapeutics.com
公司代码DNLI
上市日期Dec 08, 2017
CEODr. Ryan J. Watts, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.46M
--
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
765.12K
-0.38%
Dr. Carole Ho, M.D.
Dr. Carole Ho, M.D.
Chief Medical Officer, Head of Development
Chief Medical Officer, Head of Development
424.80K
+10.66%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
352.53K
+1.74%
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
72.72K
+9.05%
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
27.53K
+28.08%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
26.07K
+30.13%
Dr. Marc Tessier-Lavignec, Ph.D.
Dr. Marc Tessier-Lavignec, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven E. (Steve) Krognes
Mr. Steven E. (Steve) Krognes
Director
Director
--
--
Ms. Nancy A. Thornberry
Ms. Nancy A. Thornberry
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.46M
--
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
765.12K
-0.38%
Dr. Carole Ho, M.D.
Dr. Carole Ho, M.D.
Chief Medical Officer, Head of Development
Chief Medical Officer, Head of Development
424.80K
+10.66%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
352.53K
+1.74%
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
72.72K
+9.05%
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
27.53K
+28.08%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
Baillie Gifford & Co.
8.18%
The Vanguard Group, Inc.
8.06%
BlackRock Institutional Trust Company, N.A.
6.75%
Fidelity Management & Research Company LLC
5.07%
Biogen Inc
4.89%
其他
67.05%
持股股东
持股股东
占比
Baillie Gifford & Co.
8.18%
The Vanguard Group, Inc.
8.06%
BlackRock Institutional Trust Company, N.A.
6.75%
Fidelity Management & Research Company LLC
5.07%
Biogen Inc
4.89%
其他
67.05%
股东类型
持股股东
占比
Investment Advisor
52.49%
Investment Advisor/Hedge Fund
22.22%
Hedge Fund
11.87%
Sovereign Wealth Fund
6.36%
Individual Investor
4.93%
Corporation
4.89%
Research Firm
2.15%
Pension Fund
0.51%
Bank and Trust
0.36%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
524
153.05M
105.35%
-12.26M
2025Q1
537
151.12M
104.03%
-14.77M
2024Q4
523
145.56M
100.28%
-21.13M
2024Q3
518
152.07M
106.51%
-14.19M
2024Q2
504
147.18M
103.45%
-5.80M
2024Q1
491
145.33M
102.36%
+2.75M
2023Q4
499
138.06M
99.94%
+3.21M
2023Q3
492
132.50M
96.48%
-2.55M
2023Q2
504
131.32M
95.95%
-3.31M
2023Q1
503
131.21M
95.98%
-630.06K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Baillie Gifford & Co.
12.09M
8.32%
-223.89K
-1.82%
Mar 31, 2025
The Vanguard Group, Inc.
11.77M
8.1%
-221.47K
-1.85%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
10.04M
6.91%
-56.41K
-0.56%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.29M
5.02%
-712.15K
-8.90%
Mar 31, 2025
Biogen Inc
7.16M
4.93%
-5.60M
-43.89%
Oct 30, 2024
T. Rowe Price Associates, Inc.
4.26M
2.93%
+1.30M
+43.69%
Mar 31, 2025
Wellington Management Company, LLP
11.41M
7.85%
+1.56M
+15.86%
Mar 31, 2025
Temasek Holdings Pte. Ltd.
5.36M
3.69%
--
--
Mar 31, 2025
Capital Research Global Investors
4.77M
3.28%
-712.07K
-13.00%
Mar 31, 2025
State Street Global Advisors (US)
4.46M
3.07%
-84.22K
-1.85%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
iShares Neuroscience and Healthcare ETF
4.12%
Global X Guru Index ETF
1.26%
ALPS Medical Breakthroughs ETF
1.21%
Virtus LifeSci Biotech Clinical Trials ETF
1.09%
BNY Mellon Innovators ETF
0.49%
SPDR S&P Biotech ETF
0.42%
Global X Aging Population ETF
0.33%
Direxion Daily S&P Biotech Bull 3X Shares
0.27%
iShares Health Innovation Active ETF
0.25%
ProShares Ultra Nasdaq Biotechnology
0.22%
查看更多
iShares Neuroscience and Healthcare ETF
占比4.12%
Global X Guru Index ETF
占比1.26%
ALPS Medical Breakthroughs ETF
占比1.21%
Virtus LifeSci Biotech Clinical Trials ETF
占比1.09%
BNY Mellon Innovators ETF
占比0.49%
SPDR S&P Biotech ETF
占比0.42%
Global X Aging Population ETF
占比0.33%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.27%
iShares Health Innovation Active ETF
占比0.25%
ProShares Ultra Nasdaq Biotechnology
占比0.22%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
